DAIICHI SANKYO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 20
- Registration Number
- NCT00185055
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1900
- Registration Number
- NCT00185133
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-12-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 60
- Registration Number
- NCT00185094
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 534
- Registration Number
- NCT00185042
Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 45
- Registration Number
- NCT00185107
- Locations
- 🇺🇸
Medical Office, Statesville, North Carolina, United States
🇺🇸Scripps Clinic, San Diego, California, United States
🇺🇸Linder Clinical Trial Center, Cincinnati, Ohio, United States
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 152
- Registration Number
- NCT00185120
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸Apex Research Institute, Santa Ana, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 362
- Registration Number
- NCT00151775
Olmesartan Pediatric Pharmacokinetic (PK) Study
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT00151814
Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2008-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 780
- Registration Number
- NCT00151762
WelChol® and Insulin in Treating Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 260
- Registration Number
- NCT00151749
© Copyright 2024. All Rights Reserved by MedPath